2013

Primary prevention of cardiovascular disease with a Mediterranean diet

Top

Estruch R, Ros E, Salas-Salvadó, et al; for the PREDIMED study investigators. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368(14):1279-1290. The PREDIMED study (Prevención con Dieta Mediterránea) was a parallel-group, multicenter, randomized trial examining the potential benefits of a Mediterranean-style diet for primary prevention of cardiovascular disease (CVD).

Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes

Top

The Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145-154. No reduction in the composite CV primary outcome of first occurrence of death from CV causes, nonfatal MI, nonfatal stroke, or hospitalization for angina, was seen with intensive lifestyle intervention in the Look AHEAD study.

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea

Top

Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 2013;36(9):2508-2515. Canagliflozin was shown to be noninferior to sitagliptin for A1C lowering in the CANTATA-D2 trial, a 52-week study which compared these antihyperglycemic agents as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin plus sulfonylurea treatment.

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

Top

Exclusive! Expert commentary from Silvio E. Inzucchi, MD, on SAVOR-TIMI 53. Scirica BM, Bhatt DL, Braunwald E, et al; for the SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317-1326.

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.

Top

Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;381(9861):117-124. DURATION (Diabetes Therapy Utilization: Researching Changes in A1C, Weight, and Other Factors Through Intervention with Exenatide Once-Weekly) is a series of multinational studies comparing once-weekly exenatide with other antihyperglycemic therapies for treatment of type 2 diabetes.

Randomized study comparing basal bolus with basal + correction insulin regimen for hospital management of patients with type 2 diabetes: Basal Plus Trial

Top

Exclusive! Expert commentary from Vivian A. Fonseca, MD, on the Basal Plus Trial. Umpierrez GE, Smiley D, Hermayer K, et al. Randomized study comparing a basal bolus with a basal plus correction insulin regimen for the hospital management of medical and surgical patients with type 2 diabetes: Basal Plus Trial. Diabetes Care. 2013;36(8):2169-2174. In this study, Umpierrez and colleagues explored the hypothesis that a single daily dose of basal insulin plus one other corrective dose of glulisine as needed with a meal might result in similar glycemic control and a lower rate of hypoglycemia than a basal bolus regimen.

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

Top

Stenlöf K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15(4):372-382. Canagliflozin monotherapy showed significant A1C and fasting plasma glucose (FPG) reductions compared with placebo among subjects with type 2 diabetes inadequately controlled with diet and exercise in the CANTATA-M trial.

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

Top

White WB, Cannon CP, Heller SR, et al for the EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327-1335.

Coronary calcium score predicts cardiovascular mortality in diabetes

Top

Agarwal S, Cox AJ, Herrington DM, et al. Coronary calcium score predicts cardiovascular mortality in diabetes . Diabetes Care. 2013;36(4):972-977. Diabetes is a coronary heart disease (CHD) risk equivalent. The high overall mortality seen with diabetes is driven by increased cardiovascular mortality. In fact, coronary artery disease (CAD) is the most common cause of death in type 2 diabetes, and all cardiovascular disease (CVD) manifestations are two times more common among patients with type 2 diabetes.

Impact of specific glucose-control strategies on microvascular and macrovascular outcomes in 58,000 adults with type 2 diabetes

Top

Neugebauer R, Fireman B, Roy JA, O’Connor PJ. Impact of specific glucose-control strategies on microvascular and macrovascular outcomes in 58,000 adults with type 2 diabetes. Diabetes Care. 2013;36:3510-3516.

1 2 3 4 5 6 7 Next